Inclusion of albumin as a target in therapy guidelines: Guidelines for chronic kidney disease

Kidney International, Supplement

Volumn 66, Issue 92, 2004, Pages

  Warnock, David G ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b AusAM Inc ^*  (United States)

^c NATIONAL KIDNEY FOUNDATION   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

ACE inhibitors; ARBs; K DOQI; NKF; Treatment

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT PLANNING; URINARY EXCRETION; ALBUMINURIA; CHRONIC KIDNEY FAILURE; NEPHROLOGY; REVIEW; STANDARD;

ALBUMINURIA; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PRACTICE GUIDELINES;

EID: 16644395413     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09230.x     Document Type: Article

References (19)

1. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:S1-266, 2002
2. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
3. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
4. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
5. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
6. REMUZZI G, SCHIEPPATI A, RUGGENENTI P: Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145-1151, 2002
7. GAEDE P, VEDEL P, LARSEN N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
8. De ZEEUW D, REMUZZI G, PARVING HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65:2309-2320, 2004
9. U.S. RENAL DATA SYSTEM: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003
10. DAHLOF B, DEVEREUX RB, KJELDSEN SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995-1003, 2002
11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002
12. YUSUF S, SLEIGHT P, POGUE J, et al: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
13. EKNOYAN G, HOSTETTER T, BAKRIS GL, et al: Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42:617-622, 2003
14. GROSS ML, EL-SHAKMAK A, SZABO A, et al: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 46:856-868, 2003'
15. AMANN K, NICHOLS C, TORNIG J, et al: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11:1003-1011, 1996
16. AGARWAL R: Proinflammatory effects of oxidative stress in chronic kidney disease: Role of additional angiotensin II blockade. Am J Physiol Renal Physiol 284:F863-869, 2003
17. AGARWAL R, VASAVADA N, SACHS NG, CHASE S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289, 2004
18. AGARWAL R, CAMPBELL RC, WARNOCK DG: Oxidative stress in hypertension and chronic kidney disease: Role of angiotensin II. Semin Nephrol 24:101-114, 2004
19. COMPER WD, JERUMS G, OSICKA TM: Differences in urinary albumin detected by four immunoassays and high-performance liquid chromatography. Clin Biochem 37:105-111, 2004